Comprehensive Biophysical Characterization — Thermal Stability, Aggregation Profiling, Higher-Order Structure & Comparability
Creative Proteomics offers an integrated biophysical characterization platform covering the full spectrum of protein stability and structural analysis. From early developability screening through comparability, we deploy DSC, nanoDSF, SEC-MALS, DLS, SV-AUC, CD, and mass photometry in orthogonal combinations tailored to your development stage.
Core Capabilities:
Biophysical characterization is the systematic analysis of protein higher-order structure, thermal and colloidal stability, and aggregation behavior using physical measurement techniques. Unlike primary structure analysis (sequencing, peptide mapping) which confirms the amino acid composition, biophysical methods probe the folded conformation, thermodynamic stability, and solution behavior of proteins — attributes that directly impact therapeutic efficacy, immunogenicity risk, and manufacturing robustness.
Regulatory guidance including ICH Q6B expects comprehensive biophysical characterization for biotechnological products. The industry standard reflects that no single method is sufficient for complete characterization — the most reliable approach combines orthogonal techniques that probe different physical properties, providing independent confirmation of structural integrity and stability. The most reliable approach combines orthogonal techniques that probe different physical properties, providing independent confirmation of structural integrity and stability.
Biophysical characterization is central to developability assessment — the structured evaluation of a protein candidate's suitability for development as a therapeutic. Early developability screening uses minimal-sample techniques (nanoDSF, DLS) to rank candidates by stability and aggregation risk. As candidates progress through lead selection, DSC and SEC-MALS provide quantitative data for more detailed comparisons. For late-stage programs, orthogonal CD, fluorescence, and AUC methods support comparability and regulatory engagement.
If your development program requires a clear understanding of protein stability, structure, and aggregation behavior — from candidate selection through comparability — this platform provides the orthogonal characterization data you need.
Orthogonal Methods in One Platform
DSC, nanoDSF, SEC-MALS, DLS, SV-AUC, CD, and mass photometry are available directly — not through subcontracting. Consistent data interpretation across methods and a single scientific point of contact for your entire characterization package.
Stage-Appropriate Method Depth
Early candidate screening may only need nanoDSF + DLS (minimal sample, rapid results). Lead selection adds DSC + SEC-MALS for quantitative stability and aggregation profiling. Comparability studies add full CD + fluorescence + AUC for orthogonal structural fingerprinting.
ICH Q6B-Aligned Data Packages
Our biophysical characterization reports are structured around ICH Q6B expectations for higher-order structure, thermal stability, and aggregation — supporting internal decision-making from candidate selection through regulatory engagement.
Research-Phase Focus, Practical Turnaround
Services designed for development-stage programs where speed and data interpretability matter most. Flexible scheduling, direct scientist-to-scientist communication, and reports focused on actionable insights.
Each characterization area below is supported by orthogonal techniques chosen for the specific analytical question. Methods are deployed in combinations appropriate to your development stage — from early screening to regulatory-supportive comparability.
Biophysical characterization supports multiple stages of protein therapeutic development, from early candidate screening through regulatory engagement.
| Application | Key Techniques | Objective |
| Monoclonal Antibody Developability | nanoDSF, DSC, DLS, SEC-MALS | Rank lead candidates by thermal stability and aggregation propensity; identify sequences with favorable developability profiles before committing to costly manufacturing scale-up |
| Biosimilar Comparability | DSC, CD, Fluorescence, AUC | Demonstrate structural similarity between biosimilar and reference product using orthogonal methods per ICH Q5E; generate regulatory-supportive data packages |
| Formulation & Excipient Screening | nanoDSF, DLS | Screen buffer, pH, salt, and excipient conditions for optimal thermal and colloidal stability; identify formulation conditions that minimize aggregation during storage |
| Gene Therapy Vector (AAV) Characterization | SEC-MALS, DLS, SV-AUC, Mass Photometry | Quantify empty/full capsid ratios, aggregation, and capsid integrity for process development and lot comparability |
| Process Change Comparability | DSC, CD, Fluorescence, SEC-MALS | Evaluate whether manufacturing process changes affect product quality attributes; orthogonal fingerprinting provides confidence that the product remains comparable |
| Forced Degradation & Stress Stability | DSC, nanoDSF, DLS, SEC-MALS | Compare degradation pathways and stability under thermal, oxidative, photolytic, and freeze-thaw stress; identify the most stability-indicating conditions for QC method development |
| I want to know... | Primary Method | Orthogonal / Confirmatory | Typical Output |
| What is my protein's melting temperature? | DSC | nanoDSF | Tm, ΔH, domain-by-domain unfolding |
| Is my protein aggregating? | DLS | SEC-MALS | Rh, PDI, aggregate % per peak |
| What is the oligomeric state? | SEC-MALS | SV-AUC or Mass Photometry | Absolute MW, mass distribution |
| Is my protein correctly folded? | Far-UV CD | Near-UV CD / Intrinsic Fluorescence | 2° structure, 3° fingerprint |
| Which buffer stabilizes best? | nanoDSF | DLS | Tm and aggregation onset across conditions |
| Are two samples structurally comparable? | DSC | CD + Fluorescence | Thermodynamic and spectroscopic overlay |
Early Developability Screening
nanoDSF for thermal stability (Tm) and DLS for aggregation propensity. Minimal sample required (~10-20 µL each). Identifies unstable or aggregation-prone candidates before investing in deeper characterization.
Lead Selection & Characterization
DSC for full thermodynamic fingerprint + SEC-MALS for absolute MW and aggregate quantification. Quantitative stability data for lead ranking and candidate selection decisions.
Higher-Order Structure Confirmation
Far-UV and near-UV CD for secondary and tertiary structure analysis. Intrinsic fluorescence for sensitive tertiary structure monitoring. Confirms correct folding and conformational integrity.
Formulation & Stability Optimization
nanoDSF and DLS for high-throughput screening of buffer, pH, and excipient conditions. Identify optimal formulation conditions that maximize thermal stability and minimize aggregation.
Comparability & Orthogonal Confirmation
DSC + CD + fluorescence + AUC for comprehensive orthogonal comparison. Supports biosimilarity assessment, process change evaluation, and regulatory engagement per ICH Q5E/Q6B.
Data Integration & Reporting
Integrated characterization report with orthogonal method data, comparative analysis, and written interpretation for internal decision-making and regulatory-supportive documentation.
| Technique | Typical Sample Requirement |
| nanoDSF | ~10-20 µg, 10 µL at 0.1-150 mg/mL; label-free; wide buffer compatibility |
| DSC | ~50-200 µg per scan; 300 µL at 0.5-5 mg/mL; requires matched buffer reference |
| DLS | ~20-80 µL at 0.5-2 mg/mL; minimal preparation; wide buffer compatibility |
| SEC-MALS | ~50-200 µg per injection; 50-100 µL at 0.5-5 mg/mL; requires SEC column-compatible buffer |
| SV-AUC | ~400 µL at ≥0.5 mg/mL; matrix-free; formulation buffer compatible |
| CD (far-UV + near-UV) | ~200-400 µL at 0.1-0.5 mg/mL (far-UV); 1-2 mg/mL (near-UV); requires UV-transparent buffer |
| Mass Photometry | ~5-20 µL at 10-100 nM; minimal preparation; wide buffer compatibility |
| Intrinsic Fluorescence | ~100-200 µL at 0.05-0.2 mg/mL; compatible with most standard biochemical buffers |
For a comprehensive orthogonal characterization package (DSC + nanoDSF + DLS + SEC-MALS + CD), approximately 1-2 mg of purified protein at 0.5-5 mg/mL is generally sufficient. Exact requirements depend on protein concentration, molecular weight, and the specific methods selected. Contact our team for a sample requirement assessment tailored to your protein and characterization goals.
Integrated Characterization Data with Expert Interpretation
Each biophysical characterization project delivers a complete, interpreted data package. The emphasis is on orthogonal method concordance and clear, actionable conclusions.
Thermal Stability Report
DSC thermograms and nanoDSF unfolding curves with Tm, Tonset, and thermodynamic parameters for each sample and condition.
Aggregation & Size Distribution
DLS size distributions, SEC-MALS chromatograms with molar mass overlay, and aggregate quantification with orthogonal method concordance.
Higher-Order Structure Analysis
CD far-UV and near-UV spectral overlays, fluorescence emission profiles, and secondary structure content deconvolution.
Which biophysical methods should I start with for a new protein candidate?
For early developability screening, we recommend nanoDSF for thermal stability (Tm) and DLS for aggregation propensity. These techniques require minimal sample (~10-20 µL each) and provide rapid go/no-go data. As candidates progress, add DSC for detailed thermodynamic fingerprinting and SEC-MALS for absolute MW and aggregate quantification.
What is the difference between DSC and nanoDSF for thermal stability?
DSC directly measures the heat capacity change during unfolding, providing true thermodynamic parameters (Tm, ΔH, ΔCp). It is the regulatory gold standard but requires more sample and time. nanoDSF monitors intrinsic fluorescence changes during thermal ramping — label-free, higher throughput, and requires ~10 µg per measurement. nanoDSF is ideal for screening; DSC for confirmatory characterization and regulatory-supportive documentation.
How do I detect hidden aggregation that thermal stability doesn't reveal?
Two proteins can have identical Tm values but different aggregation behavior. The best practice is orthogonal characterization: DSC for thermal stability + DLS for colloidal stability + SEC-MALS for absolute MW confirmation. Published studies have demonstrated antibodies with similar DSC profiles where one showed increased hydrodynamic radius and oligomerization — revealing hidden aggregation risk that thermal stability alone missed.
What sample amounts are needed for a comprehensive biophysical characterization package?
Typical requirements range from ~10 µg (nanoDSF) to ~200 µg (SEC-MALS) per measurement. For a comprehensive orthogonal package including DSC, nanoDSF, DLS, SEC-MALS, and CD, approximately 1-2 mg of purified protein at 0.5-5 mg/mL is generally sufficient. Exact requirements depend on protein concentration, molecular weight, and the specific methods selected.
Online Inquiry